Biostock: “Chordate raising capital for continued market establishment”

Biostock reports in a new article about Chordate’s ongoing rights issue, the market establishment of Ozilia, and the exit strategy.

“The company’s strategy is expected to build up the value of its operations ahead of a successful sale to a larger player. The strategy is based on the overarching trend in the medtech and pharmaceutical market, where major players acquire smaller companies that have demonstrated proof-of-concept and market potential instead of conducting early-stage product development in-house. In recent years, many major players have invested in neurostimulation, which is the area in which Chordate Medical operates,” writes Biostock.

Read the full article (In Swedish)

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy